CSI Market
Sign In | Register

Taro Pharmaceutical Industries Ltd (TARO) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access TARO Annual Cash Flow →
Cash flow data covering Taro Pharmaceutical Industries Ltd–Mar 31 2022 offers a view into how Mar 31 2023's cash position has developed alongside business activity.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Mar 31 2023)
12 Months 		0 0 0 (Mar 31 2022)
Operating Activities
Income25.45
Depreciation & amortization32.13
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Asset Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories-16.92
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Property Plant Equipment0.00
Share-based Compensation0.00
Income (Loss) from Equity Method Investments0.00
Financial Instruments and Foreign Currency Transaction0.00
Change In Deferred Charges And Other Assets-
Gain Loss On Sale Of Long Lived Assets-
Marketable Securities Realized Gain Loss-
Gain Loss On Derivative Instruments Net Pretax-
Effect Of Exchange Differences On Inter Company Balances-
Decrease Increase In Long Term Debt Due To Currency Fluctuations-
Increase Decrease In Other Receivables Prepaid Expenses And Other-
Decrease Increase In Long Term Receivables And Other Assets-
Income taxes13.32
Proceeds from (Payments for) Trading Securities, Short-term0.00
Accounts Receivable2.24
Accounts Payable-74.03
Accrued Expense0.00
Deferred Revenue and Customer Advances and Deposits0.00
Prepaid Expense and Other Assets0.00
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities41.42
Discontinued operations0.00
Net Cash flow from Operating Activities31.75
Investing Activities
Capital Expenditures-17.87
Sale of Capital Items0.00
Payments for (Proceeds from) Short-term Investments, Total-72.39
Payments to Acquire Marketable Securities-899.76
Real Estate Investments0.00
Investment In Other Intangible Assets-
Investment In Short Term Bank Deposits-
Proceeds From Investment In Long Term Deposits And Other Assets-
Payments For Proceeds From Sale Of Long Lived Assets-
Payments For Proceeds From Acqusitions Net Of Sale Of Long Lived Assets-
Proceeds from Sale of Restricted Investments0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Cash Acquired from Acquisition0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net866.45
Discontinued operations0.00
Net Cash Flow from Investing Activities-125.56
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.00
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Proceeds From Issuance Of Shares Net-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities0.00
Effect of exchange rate on cash flow-2.83
Discontinued operations0.00
Free Cash Flow13.88
Total Cash Flow-96.64
4 historic quarters locked

Sign in to unlock the full Taro Pharmaceutical Industries Ltd cash flow history.

Sign In Create Free Account

About Taro Pharmaceutical Industries Ltd Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0000950170-23-030778

Figures are derived from filed reports and may be restated. Historical data is subject to revision.